Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
Sickle cell anemia (SCA) is one of the most neglected diseases worldwide, according to the World Health Organization.
1 Brazil site
18 to 60 Years
N/A
Vaso-occlusive crisis in Sickle cell disease might alter myocardial function through micro vascular obstruction.
1 France site
> 18 Years
Worldwide, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) annually.
1 Uganda site
3 to 9 Years
Sickle Cell Anaemia, SCA
Phase 3
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).
1 United States site
2 to 30 Years
Early Phase 1
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
3 United States sites
18 to 50 Years
Phase 1/Phase 2
Background: Venous thromboembolism (VTE) includes the abnormal clotting of blood in a deep vein of the upper or lower limbs (deep vein thrombosis) that may travel to and block a blood vessel in the lung (pulmonary embolism).
1 United States site
18 to 80 Years
HbSS, HbSC, HbAS
This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for children and young adults with Sickle Cell Disease (SCD).
1 United States site
2 to 25 Years
Phase 2
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants.
1 United States site
> 18 Years
SCA, HbSS
Phase 1/Phase 2
As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.
61 France site
5 Germany sites
4 French Guiana sites
4 Italy sites
2 Guadeloupe sites
2 Martinique sites
1 Greece site
> 2 Years
This is a single arm pilot study of peripheral stem cell transplantation (PSCT) with ex vivo t-cell receptor alpha beta+(TCRαβ+) T cell and cluster of differentiation 19+ beta (CD19+ B) cell depletion of unrelated donor (URD) grafts using the CliniMACS device in patients with sickle cell disease (SCD) and beta thalassemia major (BTM).
1 United States site
2 to 25 Years
Hemoglobin SS, Hemoglobin SC
N/A
